Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) just unveiled an update.
Shanghai Bio-heart Biological Technology Co., Ltd. has announced the successful completion of the first commercial procedure using its Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System in Switzerland, marking a significant milestone in its global expansion strategy. This development, supported by a strategic partnership with Biosensors International Group, Ltd., positions the company as a leader in the renal denervation market, with its system being the only one approved globally for both transradial and transfemoral approaches, potentially enhancing safety, efficacy, and cost-effectiveness of outpatient procedures.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-heart Biological Technology Co., Ltd. operates in the medical technology industry, focusing on the development of innovative cardiovascular solutions. The company, through its subsidiary Shanghai AngioCare Medical Technology Co., Ltd., specializes in renal denervation systems, with a market focus that includes Europe, the Asia-Pacific region, and Latin America.
Average Trading Volume: 2,453,435
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.14B
Learn more about 2185 stock on TipRanks’ Stock Analysis page.